Eden vs Henry Meds: Compounded GLP-1 Compared
Eden and Henry Meds are two of the most established compounded GLP-1 platforms. Eden differentiates with brand-name access (Wegovy, Zepbound, Ozempic, Mounjaro) sitting alongside its compounded line; Henry Meds emphasizes oral-dissolving and sublingual semaglutide options for needle-averse patients.
Reader-supported, we may earn a commission through links on this site. Rankings are editorially independent. Disclosure · Methodology
Eden and Henry Meds are both compounded GLP-1 specialists with a focus on pricing transparency and affordability. Both platforms prescribe compounded semaglutide and tirzepatide through licensed pharmacy partners and have built their positioning around being the low-cost alternative to brand-name GLP-1s. The key differences are in their pharmacy partnerships, formulary breadth, and clinical oversight model.
Henry Meds has been in the compounded GLP-1 market longer and has a more established track record of pharmacy transparency. Eden is a newer entrant with competitive pricing and a streamlined onboarding process. Both require a licensed prescriber consult before dispensing. The choice between them often comes down to which platform has better pricing at your specific dose tier — both are worth comparing directly before committing.
Eden
Flat upfront pricing with the same dose-equal cost across both compounded and brand-name GLP-1s.
Henry Meds
Affordable subscription telehealth with one of the largest compounded formularies in the industry.
Side-by-Side Comparison
| Attribute | Eden | Henry Meds |
|---|---|---|
| Program Fee | No membership fee | Included in monthly plan |
| Medication From | From $129 – $399/mo | From $129 – $349/mo |
| Editor Score | 4.5 / 5 | 4.6 / 5 |
| Primary Category | GLP-1 Weight Loss | GLP-1 Weight Loss |
| FDA Brand-Name Access | Ozempic, Wegovy, Zepbound, Mounjaro | KYZATREX |
| Compounded Options | 2 compounds | 9 compounds |
| Adjacent Categories | GLP-1 Weight Loss, TRT & Men's Hormones, Women's Health & HRT, Erectile Dysfunction |
What the Studies Actually Show
Compounded GLP-1 medications are not FDA-approved; they are prepared by 503A or 503B compounding pharmacies under FDA compounding laws and state regulation. Efficacy is inferred from the underlying active ingredient, semaglutide studied in the STEP 1 trial (NEJM 2021) and tirzepatide in SURMOUNT-1 (NEJM 2022). Sublingual and oral-dissolving formulations have less published bioequivalence data than injectable forms.
| Endpoint | Eden | Henry Meds |
|---|---|---|
| Underlying active ingredients | Semaglutide (compounded + brand) and tirzepatide (compounded + brand) | Semaglutide (injectable + sublingual) and tirzepatide (injectable) |
| Mean weight loss in pivotal trials of the active ingredients1,2 | Semaglutide 2.4 mg: −14.9% over 68 weeks · Tirzepatide 15 mg: −20.9% over 72 weeks | Same, efficacy depends on the molecule, not the brand |
| Sublingual semaglutide bioavailability3 | Not offered | Limited published bioequivalence data versus injectable |
| Brand-name GLP-1 access | Wegovy, Zepbound, Ozempic, Mounjaro available as eligible upgrades | Compounded only at present |
| Adjacent formulary (non-GLP-1) | Limited | ED, TRT, hair loss, and women's hormones available on the same platform |
Note on sublingual semaglutide bioavailabilitySublingual and oral-dissolving routes are convenient but have weaker pharmacokinetic evidence than the once-weekly injection studied in the STEP and SUSTAIN trials.
The Verdict
Choose Eden if you want the option to upgrade to FDA-approved brand-name GLP-1 without changing platforms. Choose Henry Meds for the broader compounded formulary, including ED and TRT, plus oral-dissolving semaglutide.
Frequently Asked Questions
- STEP 1 Trial. NEJM 2021 · Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021;384:989–1002.
- SURMOUNT-1 Trial. NEJM 2022 · Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022;387:205–216.
- FDA Statement on Compounded GLP-1 Drugs (2024) · FDA. Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss. U.S. Food and Drug Administration.
RxNotebook is an editorial publication. Citations point to peer-reviewed journals, FDA labeling, and clinical society guidelines. We are not affiliated with the studies cited above. This page is for general information and is not medical advice.